ZIMMER BIOMET HOLDINGS, INC. (ZBH) Stock
ZBH has an Alpha Score of 53 out of 100 (weak), computed on Nov 6, 2026 from 3 of 4 sub-scores. 9 members of Congress disclosed 18 trades in ZBH since 2016: 8 purchases and 10 sales, most recently Alan Armstrong (purchase, Mar 27, 2026). 7 of the hedge funds AlphaScala tracks reported ZBH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $299.38M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 22.7 and its net margin 9.5% (key statistics as of Nov 3, 2026).
What is ZBH's Alpha Score?
How it works →Alpha Score of 53 reflects moderate overall profile with strong momentum, weak value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 6, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded ZIMMER BIOMET HOLDINGS, INC. (ZBH)?
Most recent: Alan Armstrong (purchase, Mar 27, 2026); records start Jul 25, 2016.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-05-15 | sale | $1k – $15k |
| Rob Bresnahan R-PA · House | 2025-04-08 | purchase | $1k – $15k |
| Julie Johnson D-TX · House | 2025-02-11 | sale | $1k – $15k |
| Van Taylor R-TX · House | 2022-11-28 | sale | $100k – $250k |
| Lois Frankel D-FL · House | 2022-07-28 | sale | $1k – $15k |
| Lois Frankel D-FL · House | 2022-06-13 | partial sale | $1k – $15k |
| Lois Frankel D-FL · House | 2021-12-10 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all ZBH political trades →Which hedge funds own ZBH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 3.48M | $299.38M | +152% |
| Point72 Steve Cohen | 880K | $75.75M | NEW |
| Millennium Management Israel Englander | 222K | $19.12M | NEW |
| Marshall Wace | 145K | $12.44M | NEW |
| Bridgewater Associates Ray Dalio | 36K | $3.11M | +6% |
| D.E. Shaw David Shaw | 24K | $2.08M | +164% |
| Blackstone | 4K | $305.8K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are ZIMMER BIOMET HOLDINGS, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 11, 26 | Thornal Kevin R | Grp Pres-Global Business | SELL | 5.7K | $529K |
| Sep 4, 26 | Phipps Chad F | See remarks below. | SELL | 3.0K | $295K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are ZBH's key statistics?
Key statistics as of Nov 3, 2026
How does ZBH's valuation compare with the Healthcare sector?
| Metric | ZBH | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 22.7 | 28.8 | 111 |
| Net margin | 9.48% | 4.31% | 164 |
| Return on equity | 6.35% | 5.47% | 185 |
| Dividend yield (payers) | 1.04% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 7, 2026). P/E excludes loss-making companies.
ZBH price chart
Powered by TradingViewWhat does ZIMMER BIOMET HOLDINGS, INC. do?
Zimmer Biomet Holdings, Inc. is a global medical technology company that designs, manufactures, and markets orthopedic reconstructive products for joint replacement and repair. The company provides a comprehensive portfolio including knee and hip implants, sports medicine and biologics products, extremities and trauma solutions, craniomaxillofacial and thoracic reconstructive products, spine implants, office-based surgical technologies, and dental implants. Zimmer Biomet serves patients, surgeons, and healthcare systems across multiple geographical markets including the Americas, Europe, Middle East, Africa, and Asia Pacific regions. The company has pursued strategic acquisitions and divestitures to strengthen its product lineup and expand its pipeline, demonstrating commitment to innovation in orthopedic solutions. With recent advancements including robotic-assisted surgical systems and iodine-treated implant technologies, Zimmer Biomet maintains a significant presence in the orthopedic reconstructive market. Founded in 1927 and headquartered in Warsaw, Indiana, the company operates as a key player in the medical device industry, focusing on improving musculoskeletal health outcomes globally.